Please login to the form below

Not currently logged in
Email:
Password:

Ixempra

This page shows the latest Ixempra news and features for those working in and with pharma, biotech and healthcare.

Bayer fails to overturn Nexavar compulsory licence in India

Bayer fails to overturn Nexavar compulsory licence in India

drugs. There have already been suggestions that Roche's breast cancer treatment Herceptin (trastuzumab) and Bristol-Myers Squibb's leukaemia medicine Sprycel (dasatinib) and chemotherapy Ixempra (ixabepilone) could follow Nexavar down

Latest news

  • India could hit Roche and BMS with compulsory licences India could hit Roche and BMS with compulsory licences

    Generic versions of Herceptin, Sprycel and Ixempra may reach market before patent expiration. ... According to the Indian Express, Herceptin, Ixempra and Sprycel cost 50, 000 rupees (687), 70, 000-80, 000 rupees (961 to 1, 098) and 15, 000 rupees (206)

  • Eisai wins approval for breast cancer drug

    and with Bristol-Myers Squibb's Ixempra (ixabepilone), which is marketed for patients with late- stage disease after failure of an anthracycline, taxane and Xeloda.

  • Bristol-Myers signs cancer drug deal

    BMS' existing cancer-drug portfolio includes Erbitux (cetuximab), Ixempra (ixabepilone) and Sprycel (dasatinib).

  • FDA approves BMS chemotherapy drug

    Ixempra was approved for use in women who have failed treatment on three other types of chemotherapy. ... Ixempra inhibits the protein tubulin, which stops cells growing and dividing by arresting the cell cycle.

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

digital launch
How can virtual pharma companies de-risk new product launches?
The risks and challenges involved in taking specialty drugs, biopharmaceuticals and drug/device combinations to market...
Not waving but drowning. Reflections on data curation in the age of information overload
...
digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...

Infographics